About: http://data.cimple.eu/news-article/0c1c42aee6a008705be71df66753d1a84117caa90fc146038f9484ec     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • Pharmaceutical group AstraZeneca announced on Wednesday that it will partner with Germany's IDT Biologika to produce more Covid-19 vaccine doses for use in Europe. The two companies are "exploring options" to accelerate output of the AstraZeneca vaccine in the second quarter of 2021, the Anglo-Swedish company said in a statement. The announcement from the vaccine manufacturer follows controversy over deliveries of the AstraZeneca jab to the European Union which has caused tensions between Brussels and London. AstraZeneca said following the decision by the European Medicines Agency (EMA) to approve the shot, the shipping of 17 million doses, which began on February 5, would continue in the coming weeks. The delivery of further doses is planned for March, the pharmaceutical group added in the statement. The agreement will see both companies invest to increase capacity at a production site in Dessau, eastern Germany to produce millions of doses per month by the end of 2022. The investment, the details of which have not yet been disclosed, could also allow for the manufacturing of coronavirus vaccines produced by other pharmaceutical companies. The plans will give IDT Biologika among the largest vaccine manufacturing capacities in Europe. "This agreement will greatly help Europe build an independent vaccine manufacturing capability that will allow it to meet the challenges of the current pandemic and create strategic supply capacity for the future," AstraZeneca's chief executive Pascal Soriot said. "I would like to thank the German Federal Government and the European Commission for their support in our efforts," he added. The AstraZeneca vaccine, developed with researchers from Oxford University, had earlier garnered praise because of its low cost relative to its rivals and the ease of storage - a regular refrigerator can be used to store the vaccine. But since then it has suffered a number of setbacks. The jab was temporarily excluded from South Africa's immunisation campaign over questions about its effectiveness against a new strain of the disease first identified in the country. There have also been concerns in some parts of Europe over using the AstraZeneca vaccine on the elderly. However on Wednesday WHO vaccine experts recommended the AstraZeneca-Oxford Covid-19 vaccine for use on people aged over 65 and in settings where variants of the virus are circulating. csp/pvh
schema:headline
  • AstraZeneca seeks to boost vaccine output for Europe with German partner
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
http://data.cimple...tology#hasEmotion
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 3 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software